Ultra-Low-Dose Systemic Tissue Plasminogen Activator in High-Risk Submassive Pulmonary Embolism.

Autor:	Guru PK; Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL; Division of Nephrology, Mayo Clinic, Jacksonville, Florida, United States of America; Department of Transplantation, Mayo Clinic, Jacksonville, Florida, United States of America. Electronic address: Guru.pramod@mayo.edu., Giri AR; Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL., Sanghavi DK; Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL; Department of Transplantation, Mayo Clinic, Jacksonville, Florida, United States of America., Ritchie C; Department of Diagnostic Radiology, Mayo Clinic, Jacksonville, FL.
Jazyk:	angličtina
Zdroj:	Mayo Clinic proceedings [Mayo Clin Proc] 2022 Jun; Vol. 97 (6), pp. 1158-1163.
DOI:	10.1016/j.mayocp.2022.02.011
Abstrakt:	Risk stratification of pulmonary embolism (PE) is vital for clinical management. While low-risk and high-risk PE management are clearly defined in many societal guidelines, the management of moderate-risk, also called submassive, PE remains unsettled. There is a subgroup of patients with submassive PE that progress to the severe category despite receiving systemic anticoagulation. The role of thrombolysis in the management of submassive PE remains to be established. We share our experience with ultra-low-dose (25-mg) systemic tissue plasminogen activator in a series of 4 patients with high-risk submassive PE. (Copyright © 2022 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu